BHCM
RYTM icon

Brevan Howard Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Brevan Howard Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,777
Closed -$328K – 2512
2026
Q1 		$328K Buy
+3,777
New +$367K ﹤0.01% 1563

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Brevan Howard Capital Management's RYTM Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2026, closing a stake of 3,777 shares — an estimated $328K sold.

Brevan Howard Capital Management first reported a position in RYTM in Q1 2026 and held it in 1 quarter. The position peaked at $328K in Q1 2026. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Rhythm Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 3,777 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $328K.
  • Brevan Howard Capital Management first reported a position in Rhythm Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Brevan Howard Capital Management's Rhythm Pharmaceuticals position peaked at $328K in Q1 2026.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.